Although GLP-1 RAs are not yet first-line therapies for nephropathy, current the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend them in patients with T2DM and CKD when SGLT2 inhibitors are contraindicated or insufficient [9,10]. The gene discussed is SLC5A2; the disease is Nephropathy.